New drug combo shows promise for tough breast cancer
NCT ID NCT07162051
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 31 times
Summary
This study tested a new drug combination for people with a common type of early breast cancer (HR+/HER2-). The goal was to see if adding the drug fluzoparib to standard chemotherapy could shrink tumors more effectively. 28 participants received the treatment before surgery. The main focus was on how much tumor remained after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+/HER2- EARLY BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Xijing hospital
Xi'an, Shaanxi, 710032, China
Conditions
Explore the condition pages connected to this study.